Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

Including First-In-Class ActRIIA Antibody

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.

Scientists (miniature) are gathering at a conference hall for a meeting.
This year’s ADA indicated that muscle-preserving drugs developed by Chinese firms for weight management are mostly in preclinical stage currently. (Shutterstock/AI-generated)

Among Chinese developers of weight management medicines presenting at the June 20–23 American Diabetes Association (ADA) congress, Sciwind Biosciences and Laekna Therapeutics appeared to be the stand-outs in terms of new data on self-developed assets — ecnoglutide in Phase III and the Phase I first-in-class combination therapy LAE102, respectively.

The Chinese-origin, clinical-stage drugs presented at the Chicago meeting were in a notably narrow band in terms of therapeutic targets,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

ESMO 25: Tolerability Raised As Exelixis STELLAR-303 Study Still Needs To Mature

 

Exelixis’s novel kinase inhibitor zanzalintinib has shown promise in a metastatic colorectal cancer population but some experts want to see more data before passing judgement on whether it can become a new chemotherapy-free treatment option for these patients.

Sanofi’s Inhibrx-Acquired Rare Disease Therapy Clears Phase II Hurdle

 
• By 

Efdoralprin alfa, which was acquired through Inhibrx, has met the endpoints of a Phase II trial for alpha-1 antitrypsin deficiency.

How To Score A Win With Real-World Evidence In India

 
• By 

Bharat Serums showed it’s possible to score a regulatory win with real-world evidence (RWE) studies in India when it ran one leading to a label expansion for its mAb trinbelimab. As cell and gene therapies and rare disease drugs gain currency, sponsors could look at takeaways from the RhYTHM study.

Summit Presses Ahead With Ivonescimab Filing Despite Approval Doubts

 

Frontrunner believes it can gain a first approval in EGFR+ lung cancer, even though the FDA recently raised the bar on overall survival.

More from Therapy Areas

Summit Presses Ahead With Ivonescimab Filing Despite Approval Doubts

 

Frontrunner believes it can gain a first approval in EGFR+ lung cancer, even though the FDA recently raised the bar on overall survival.

Neuphoria To Look At Strategic Options After BNC210 Fails In Social Anxiety

 

Neuphoria said that its Phase III trial of BNC210 in social anxiety disorder did not meet the primary or secondary endpoints, but its PTSD program will continue.

ESMO 25: Ovarian Cancer Data Validates Tubulis ADC Platform

 
• By 

Positive first-in-human data for TUB-040 represent "a momentous milestone" for the German biotech, according to its CEO Dominik Schumacher.